Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

NCT03585348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 265537

Last updated 2021-08-25

No results posted yet for this study

Summary

The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improvement projects since it is primarily individuals who determine the utilization of neuromuscular blocking drugs and reversal agents, not institutions. Therefore, the primary objective of this study is to determine the variability between individual anesthesia providers (attending physician, resident, nurse anesthetists) in the use of neuromuscular blocking drugs and reversal agents, using advanced statistical methods to adjust for differences in patient and procedure case mix. The investigators hypothesize that variance between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents differs depending on provider type.

Conditions

  • Neuromuscular Blockade
  • Residual Curarisation, Postoperative
  • Surgery Under General Anaesthesia

Interventions

OTHER

Neuromuscular blocking agents

Neuromuscular blocking agent ED95 equivalent dose by provider

Sponsors & Collaborators

Principal Investigators

  • Philipp Fassbender, MD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-29
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585348 on ClinicalTrials.gov